Terms: = Sarcomas AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Staging
12 results:
1. [
Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
[TBL] [Abstract] [Full Text] [Related]
2. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
Hirmas N; Hamacher R; Sraieb M; Ingenwerth M; Kessler L; Pabst KM; Barbato F; Lueckerath K; Kasper S; Nader M; Schildhaus HU; Kesch C; von Tresckow B; Hanoun C; Hautzel H; Aigner C; Glas M; Stuschke M; Kümmel S; Harter P; Lugnier C; Uhl W; Niedergethmann M; Hadaschik B; Grünwald V; Siveke JT; Herrmann K; Fendler WP
J Nucl Med; 2023 May; 64(5):711-716. PubMed ID: 36581374
[TBL] [Abstract] [Full Text] [Related]
3. The Role of FDG-PET and Whole-Body MRI in High Grade Bone sarcomas With Particular Focus on Osteosarcoma.
Farina A; Gasperini C; Aparisi Gómez MP; Bazzocchi A; Fanti S; Nanni C
Semin Nucl Med; 2022 Sep; 52(5):635-646. PubMed ID: 34879906
[TBL] [Abstract] [Full Text] [Related]
4. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract] [Full Text] [Related]
5.
Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
[TBL] [Abstract] [Full Text] [Related]
6. The Role of
Harrison DJ; Parisi MT; Shulkin BL
Semin Nucl Med; 2017 May; 47(3):229-241. PubMed ID: 28417853
[TBL] [Abstract] [Full Text] [Related]
7. Pretreatment tumor SUV
Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
[TBL] [Abstract] [Full Text] [Related]
8. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.
Skamene SR; Rakheja R; Dahlstrom KR; Roberge D; Nahal A; Charest M; Turcotte R; Hickeson M; Freeman C
J Surg Oncol; 2014 Apr; 109(5):410-4. PubMed ID: 24310279
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma.
Federico SM; Spunt SL; Krasin MJ; Billup CA; Wu J; Shulkin B; Mandell G; McCarville MB
Pediatr Blood Cancer; 2013 Jul; 60(7):1128-34. PubMed ID: 23255260
[TBL] [Abstract] [Full Text] [Related]
10. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
[TBL] [Abstract] [Full Text] [Related]
11. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma.
Baum SH; Frühwald M; Rahbar K; Wessling J; Schober O; Weckesser M
J Nucl Med; 2011 Oct; 52(10):1535-40. PubMed ID: 21903740
[TBL] [Abstract] [Full Text] [Related]
12. [Liver transplantation and tumors: risk and chance].
Cathomas G; Renner EL
Schweiz Med Wochenschr; 2000 Jun; 130(25):963-8. PubMed ID: 10909724
[TBL] [Abstract] [Full Text] [Related]
